Strategic Partnerships NeoImmuneTech engages in collaboration with industry leaders in immuno-oncology, including Merck and Roche, presenting partnership as a core growth channel. This indicates potential sales opportunities through co-development, licensing, or CRO/CMC support for NT-I7 programs and combination trials.

Clinical Pipeline NT-I7 stands as a lead long-acting IL-7 candidate with prior biomarker work and T cell amplification rationale, suggesting upsell opportunities with biopharma players seeking T cell–focused immunotherapies or combination strategies to enhance CPI efficacy.

Clinical Momentum Active and expanding clinical activity across oncology and infectious disease indications, with ongoing trials and biomarker analyses in tumor microenvironment, signaling potential for your team to engage as a trial site, investigator, or CRO collaborator for trial execution or data partnerships.

BD Leadership Recent leadership appointment of a President and CEO focused on business development indicates a strategic emphasis on growth, licensing, and partnerships—an opening to target the company for strategic alliances, BD outreach, and co-development discussions.

Global Expansion EU CTA activity and international collaboration with Imugene reflect a global expansion posture, creating sales opportunities in multinational trials, cross-border licensing, and regional commercialization discussions as the company scales.